Metabolic Syndrome

Dr. Ahima is a Professor of Medicine at the University of Pennsylvania. He received a BSc from the University of London, MD from the University of Ghana, and PhD from Tulane University in New Orleans, Louisiana. He did an internship and residency in internal medicine at the Albert Einstein College of Medicine, Jack D. Weiler Hospital and Jacobi Medical Center, in New York. He then moved to the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, for subspecialty training in Endocrinology, Diabetes and Metabolism, and postdoctoral research in the laboratory of Dr. Jeffrey Flier. Dr. Ahima served as Instructor in Medicine at Harvard prior to moving to Penn in 1999. He received an Owl Club Teaching Award at Tulane University School of Medicine, Leo Davidoff Award at the Albert Einstein College of Medicine, Pfizer Postdoctoral Award at Harvard Medical School, and the Albert Stunkard Founder's Award at the University of Pennsylvania. Dr. Ahima was elected to the American Society for Clinical Investigation in 2005, and the Association of American Physicians in 2010. He is board certified in Internal Medicine, and Endocrinology, Diabetes and Metabolism, and is a Fellow of the American College of Physicians, and The Obesity Society. Dr. Ahima has served as a reviewer for the National Institutes of Health, Wellcome Foundation of the United Kingdom, and the Howard Hughes Medical Institute, and is a member of the Board of Scientific Counselors of the National Institute on Alcohol Abuse and Alcoholism. Dr. Ahima is a past Associate Editor of Gastroenterology, and the Journal of Clinical Investigation, and currently a Co-Editor of the Annals of the New York Academy of Sciences Year in Diabetes and Obesity.

Foreword Preface Part 1: Epidemiology (i) Overview: Definition, prevalence in adults and children, morbidity, mortality (ii) Obesity and metabolic syndrome in North America (iii) Obesity and metabolic syndrome in Europe (iv) Obesity and metabolic syndrome in Latin America (v) Obesity and metabolic syndrome in Sub-Saharan Africa (v) Obesity and metabolic syndrome in the Middle East (vi) Obesity and metabolic syndrome in Asia (vii) Obesity and metabolic syndrome in Australia, New Zealand and Polynesia Part 2: Genetics (i) Genetics of obesity (ii) Genetics of type 2 diabetes (iii) Genetics of lipid disorders (iv) Genetics of atherosclerosis Part 3: Environmental factors (i) Gestational factors, obesity and metabolic syndrome (ii) Influence of early postnatal environment on obesity and metabolic syndrome (breast feeding, weaning, family environment) (iii) Diet, obesity and metabolic syndrome (calories, macronutrients, high fructose corn syrup, micronutrients) (iv) Exercise and non-exercise physical activity, obesity and metabolic syndrome (v) Influence of housing, transportation, TV and electronic media on obesity and metabolic syndrome (vi) Social and community networks, obesity and metabolic syndrome Part 4: Pathophysiology (i) Energy homeostasis (ii) Metabolism of carbohydrate, proteins and lipids (iii) CNS regulation of feeding and energy homeostasis (iv) Adipose tissue (structure, WAT and BAT, adipokines, fuel metabolism) (v) Gut pathophysiology (motor, exocrine, endocrine) (vi) Endocrine pancreas (alpha, beta , other cells, insulin defects in obesity) (vii) Insulin resistance and metabolic syndrome (viii) Gut microbiome, obesity and metabolism (ix) Atherogenic dyslipidemia (x) Inflammation, endothelial dysfunction, and atherogenesis (xi) Skeletal muscle, myokines and metabolism (xii) Sleep, circadian rhythms and metabolism Part 5: Diseases associated with obesity (i) Type 2 diabetes (natural history, pathogenesis, assessment of insulin resistance and beta cell dysfunction, treatment) (ii) Cardiovascular morbidity (CAD; stroke) (iii) Non-alcoholic fatty liver disease (iv) Obstructive sleep apnea, obesity and metabolic syndrome (v) Obesity, GERD, Barrett's esophagus (vii) Connecting metabolic syndrome and cancer (viii) Sarcopenic obesity (ix) Obesity, PCOS and infertility (x) Endocrinopathies associated with obesity (insulin, thyroid, glucocorticoids, growth hormone) (xi) Obesity, metabolic syndrome and dementia Part 6: Management (i) Assessment of obesity and cardiometabolic risk (body composition, laboratory investigation, imaging, novel biomarkers) (ii) Diet, exercise, behavior therapy (iii) Pharmacotherapy (iv) Bariatric surgery (v) Childhood interventions (school -based and other programs) (vi) Community, national and global interventions